• 1
    Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010; 40:38597.
  • 2
    Katz DH, Paul WE, Goidl EA, Benacerraf B. Carrier function in anti-hapten immune responses. I. Enhancement of primary and secondary anti-hapten antibody responses by carrier preimmunization. J Exp Med 1970; 132:26182.
  • 3
    Paul WE, Katz DH, Goidl EA, Benacerraf B. Carrier function in anti-hapten immune responses. II. Specific properties of carrier cells capable of enhancing anti-hapten antibody responses. J Exp Med 1970; 132:28399.
  • 4
    Valenta R, Niespodziana K, Focke-Tejkl M et al. Recombinant allergens: what does the future hold? J Allergy Clin Immunol 2011; 127:8604.
  • 5
    Focke M, Mahler V, Ball T et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J 2001; 15:20424.
  • 6
    Focke M, Linhart B, Hartl A et al. Non-anaphylactic, surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 2004; 34:152533.
  • 7
    Edlmayr J, Niespodziana K, Linhart B et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009; 182:6298306.
  • 8
    Niespodziana K, Focke-Tejkl M, Linhart B et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011; 127:156270.
  • 9
    Twaroch T, Focke M, Civaj V et al. Carrier-bound, non-allergenic Ole e 1 peptides for vaccination against olive pollen allergy. J Allergy Clin Immunol 2011; 128:17884.
  • 10
    Chen KW, Focke-Tejkl M, Blatt K et al. Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. Allergy 2012; 67:60921.
  • 11
    Twaroch TE, Focke M, Fleischmann K et al. Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy. Clin Exp Allergy 2012; 42:96675.
  • 12
    Linhart B, Valenta R. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine 2012; 30:432835.
  • 13
    Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:76171.
  • 14
    Valenta R, Ferreira F, Focke-Tejkl M et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010; 28:21141.
  • 15
    Mothes N, Heinzkill M, Drachenberg KJ et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33:1198208.
  • 16
    Niederberger V, Horak F, Vrtala S et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004; 101(Suppl 2):1467782.
  • 17
    Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355:144555.
  • 18
    van Neerven RJ, Wikborg T, Lund G et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4 +  T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999; 163:294452.
  • 19
    Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004; 4:3138.
  • 20
    Breiteneder H, Pettenburger K, Bito A et al. The gene coding for the major birch pollen allergen Bet v 1, is highly homologous to a pea disease resistance response gene. EMBO J 1989; 8:19358.
  • 21
    Niederberger V, Pauli G, Grönlund H et al. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. J Allergy Clin Immunol 1998; 102:57991.
  • 22
    Kazemi-Shirazi L, Pauli G, Purohit A et al. Quantitative IgE inhibition experiments with purified recombinant allergens indicate pollen-derived allergens as the sensitizing agents responsible for many forms of plant food allergy. J Allergy Clin Immunol 2000; 105:11625.
  • 23
    Bauer L, Bohle B, Jahn-Schmid B et al. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Clin Exp Immunol 1997; 107:53641.
  • 24
    Vrtala S, Hirtenlehner K, Vangelista L et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997; 99:167381.
  • 25
    Vrtala S, Hirtenlehner K, Susani M et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001; 15:20457.
  • 26
    Vrtala S, Ball T, Spitzauer S et al. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. J Immunol 1998; 160:613744.
  • 27
    Linhart B, Bigenzahn S, Hartl A et al. Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy. J. Immunol 2007; 178:392431.
  • 28
    Pauli G, Larsen TH, Rak S et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122:95160.
  • 29
    Hjelm F, Carlsson F, Getahun A, Heyman B. Antibody-mediated regulation of the immune response. Scand J Immunol 2006; 64:17784.
  • 30
    Uthoff H, Spenner A, Reckelkamm W et al. Critical role of preconceptional immunization for protective and nonpathological specific immunity in murine neonates. J Immunol 2003; 1:348592.
  • 31
    Carlsson F, Hjelm F, Conrad DH, Heyman B. IgE enhances specific antibody and T-cell responses in mice overexpressing CD23. Scand J Immunol 2007; 66:26170.
  • 32
    van der Heijden FL, van Neerven RJJ, van Katwijk M, Bos JD, Kapsenberg ML. Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 1993; 150:364350.
  • 33
    Pree I, Shamji MH, Kimber I, Valenta R, Durham SR, Niederberger V. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy 2010; 40:134652.
  • 34
    Shamji MH, Francis JN, Würtzen PA, Lund K, Durham SR, Till SJ. Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. J Allergy Clin Immunol 2013; 132:10035.